Maze Therapeutics (MAZE) stock

Kidney disease medicines , market cap $1.8B

Medicines for kidney and metabolic diseases

Worth $1.8B

$35.45

+1.55%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Average

In its industry

#60of 281

Biotech

Checks firing

9of 14

Trending up

From 52-week high

-33.9%

under its best in a year

Up:Up to Average for the first time since Mar 2026. Scores before Sep 10, 2026 were rebuilt.

MAZE's Quality Score rose 2 points on Tue, Nov 10, to 8. More shares traded than usual (2 chart checks started).

Follow MAZE's trial news. Pro members can get an alert when Maze Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when MAZE files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEarly 2027“Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027”Trial data · SEC filing · Nov 9

Why is MAZE up?

Up 17% from Nov 2 to Nov 10.

Its Nov 9 results release reported a diluted loss of $0.79 a share, and its Nov 9 close was its highest since Mar 24, 2026.

Sources: Price history, Nov 10, 2026; SEC filing, Nov 9, 2026; Company release (8-K), Nov 9, 2026

1 more reason, free with an account →1 more reason why MAZE rose 17% since Nov 2, from its filings, with the timeline and its peers, for Pro members.

Key facts on MAZE

Key facts on MAZE
The chart	Stronger than 81% of stocks above every average
Its score	Up:Up to Average for the first time since Mar 2026 Scores before Sep 10, 2026 were rebuilt.
Latest filing	8-K, Nov 9 Reported its quarterly results

1 more reason behind MAZE's 8, free with an account →3 more reasons behind MAZE's 8, for Pro members.

MAZE in the news

ReportLast night: a loss of $0.79 a share. Past reports ›

What's next

Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.

2 more dates ahead: conferences, for Pro members.

MAZE catalysts

Coming up

After its last 4 reports it closed -7.1% on average, higher 3 of 4 times.

What's next for MAZE, and how long its cash lasts

Next step the company has named

Early 2027“Enrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027”Trial data · SEC filing · Nov 9

What it means: the first look at a trial’s main results, as the company reports them.

Lead program: MZE829
Another trial: CIPheRPhase 2 · Recruiting · 38 people · main data estimated Dec 2027 · NCT07694440

1 more trial, 2 more milestones and 17 filings, for Pro members.

Cash runway

The company says its cash lasts into 2029 (8-K, Nov 9).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Feb 4, 2026)
At-the-market share sales program (S-3ASR, filed Feb 4, 2026)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

CEO Jason V. Coloma sold 34,501 shares on Nov 2, under a planned sale. 41 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Jason Coloma buys or sells

For Pro members: every trade, and Jason Coloma’s 19 filings and quotes.

Get an alert when MAZE files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why MAZE scores 8

Averagefor quality, not price, 9 of 14 chart checks firingWhat the Quality Score means

+9Chart checks 9 of 14 firing right now, one point each
+2Long-term trend above a rising 200-⁠day average

Run-up adds
Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Growth, Volatility, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on MAZE and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:29 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when MAZE's Quality Score turns up

A free account. No card.

How MAZE ranks in Biotech

MAZE is #60 of 281 by Quality Score.

How MAZE ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	LXRXLexicon Pharmaceuticals		Open for its score
	LYCALycia Therapeutics		Open for its score
	MBXMBX Biosciences		Open for its score
	MDGLMadrigal Pharmaceuticals		Open for its score
60	MAZEMaze Therapeutics	9/14	8

When does MAZE report earnings, and what happens after?

Expected to report Thu Mar 25, after the close (in 135 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What MAZE reported on Nov 9, 2026

The quarter

A loss of $0.79 a share, from $0.66.

“License revenue recognized in 2026 reflects the achievement of a milestone in the first quarter of 2026 pursuant to the exclusive license agreement with Shionogi & Co., Ltd. for the rights to MZE001, an investigational oral glycogen synthase 1 (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

MAZE's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The increase primarily reflects higher expenses related to the progression of our MZE829 and MZE782 clinical development programs and higher personnel-related costs, including non-cash stock-based compensation expense.”

From its results filing (SEC filing · Nov 9)

2 more sentences, for Pro members.

The numbers

Market value: $1.8B; today
Free cash flow: -$115M; last 12 months

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on MAZE: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+4.6%+0.8%+1.6%

May 12Aug 11Nov 9

Reported	When	Gap	Reaction	5 days
Nov 9, 2026After close	After close	-1.4%	+1.6%	not yet
Aug 11, 2026After close	After close	+0.6%	+0.8%	+6.7%
May 12, 2026After close	After close	+0.8%	+4.6%	-5.1%

MAZE closed higher after 3 of its last 4 reports.

All 4 reports, and MAZE's Quality Score going into each

MAZE has 9 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on MAZE, and all 14 on every stock.Get in free →

MAZE RSI today: 70.8, above its 50-day and 200-day averages

Not scored

RSI 70.8, MACD above signal, above both averages. Not scored.13 readings

The deep dive on MAZE

What it does and how it makes money2 findingsFor Pro members2 findings on what MAZE does and how it makes money, for Pro members
Where it stands3 findings2 offerings of shares or notes since Jan 2025, $140M where the filing states the size.SEC filing · Apr 22, 2026
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades MAZE, for Pro members

7 more findings on MAZE, each with its source, for Pro members.

MAZE share count over time

Shares: 33.0% more than a year ago (to Sep 30).

Shares of MAZE outstanding, as filed
Shares outstanding	As of
54.7M	Nov 4, 2026
55.5M	Aug 5, 2026
55.3M	May 7, 2026
48.1M	Nov 3, 2025

Offerings, shelves, and splits of MAZE, from its filings
From its filings	Filed
Priced a sale of shares	Apr 22, 2026
Registered shares for a later sale (S-3ASR)	Feb 4, 2026
Registered shares for sale (S-1)	Oct 17, 2025
Raised $140M in a sale of shares, about 8% of its market value	Jan 31, 2025

MAZE insider trades

4 insiders sold $1.1M across 16 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellJason V. Coloma$293KChief Executive Officerat $26.01 on Sep 3, filed Sep 4

SellJason V. ColomaChief Executive Officer$293Kat $26.01 on Sep 3, filed Sep 4

All 16 insider filings on MAZE from the last six months, for Pro members.

All MAZE insider trades

MAZE's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Jason V. ColomaChief Executive Officer · 15 trades
Harold BernsteinPresident, R&D & CMO · 19 trades
Atul DandekarCSBO · 16 trades
Amy BachrodtSVP, Finance · 7 trades
Phillips CourtneyGC and Corp. Secretary · 4 trades
Catherine A. SohnDirector · 2 trades
Charles J. HomcyDirector · no trades on file

See insider trades by person

Which ETFs hold MAZE?

In ETFs: MAZE is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Maze Therapeutics

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

141 employeesSouth San Francisco, CAmazetx.com

What Maze Therapeutics says it competes with

“The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property.”

From its annual report, SEC filing · Mar 25, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on MAZE and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would move MAZE's score: 7 things
8 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 4Jason V. Coloma sold MAZE$293K at $26.01, filed Sep 4

Alerts are optional.

See MAZE's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: MAZE's Quality Score is 8 (Average), #60 of 281 in Biotech. Insiders sold $1.1M in the last 6 months (Form 4).

What does MAZE's Quality Score say?

MAZE scores 8 today, which Breakaway calls Average. It is #60 of 281 in Biotech by Quality Score, with 9 of 14 chart checks firing. Up 17% from Nov 2 to Nov 10. Shares: 33.0% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is MAZE's Quality Score?

MAZE scores 8 today, which Breakaway calls Average (6 to 10). That is #60 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MAZE's 8.

Are insiders buying MAZE?

4 insiders sold $1.1M across 16 filings in the last 6 months. No open-⁠market buys on record. The newest is Jason V. Coloma, Chief Executive Officer, who sold $293K on Sep 3. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.